Meditech teams up to market skin cancer treatment
10 September, 2002 by Graeme O'NeillMeditech Research and SkyePharma have completed a commercial pas-de-deux that sees them divide up the Pacific Rim markets for the Solarase, a topical treatment for the pre-cancerous skin condition, actinic or solar keratosis.
UK calls for GM animal advisory body
10 September, 2002 by Melissa TrudingerThe UK's Agriculture and Environment Biotechnology Commission has called for a new advisory body and development of a strategy to deal with issues relating to genetically modified and cloned animals.
Bionomics touts new mouse model, posts loss
09 September, 2002 by Melissa TrudingerA mouse model for inherited epilepsy has been created by Adelaide company Bionomics by 'knocking-in' the human mutation. The model exhibits seizures similar to human epileptic seizures.
Autogen wins US patent for Beacon gene
09 September, 2002 by Melissa TrudingerMelbourne biotech Autogen has been granted a US patent for its Beacon gene, and its use as a therapeutic or diagnostic in conditions like obesity, diabetes and energy imbalance.
Interview: the antisense evangelist
06 September, 2002 by Melissa TrudingerPersistence has paid off for Stanley Crooke and his company Isis Pharmaceuticals.
AusBiotech recruiting for French devices and diagnostics tour
05 September, 2002 by Iain ScottUp to 20 AusBiotech members are being offered the chance to take part in a medical devices and diagnostics mission in France this November 4-8, under the auspices of the French-Australian Industrial Research (FAIR) program.
Chemeq picks up the pace in South Africa
05 September, 2002 by Melissa TrudingerPerth-based company Chemeq has started its push to introduce its polymeric antimicrobial drug for prevention of colibacillosis in pigs into South Africa, the first country to approve the veterinary product.
MSAC decision disappoints Sirtex CEO
04 September, 2002 by David BinningThe chief executive of Sydney-based company Sirtex has expressed disappointment with the Medical Services Advisory Committee (MSAC) following its surprise rejection of a subsidy application for the company's liver cancer treatment.
Virax to extend trials for HIV/AIDS therapy
03 September, 2002 by Melissa TrudingerMelbourne-based immune therapies company Virax Holdings has announced an extension to its Phase I/IIA clinical trial to further assess the potential of its HIV/AIDS therapy.
GroPep names new CEO
02 September, 2002 by Iain ScottAdelaide-based biotech GroPep has named former Faulding Pharmaceuticals top brass Robert Finder as its new CEO.
Auspep aiming to ride the big waves
29 August, 2002 by Pete YoungAustralian peptide maker Auspep is looking for funds to finance its growth on the back of a market that is jagging upward.
Novogen subsidiary to team with Yale in cancer drug trial
29 August, 2002 by Melissa TrudingerMarshall Edwards Inc (MIE), a subsidiary of Australian pharma Novogen, has announced an agreement with Yale University's Department of Obstetrics and Gynaecology that will allow the Yale researchers to take the company's anti-cancer drug phenoxodiol into clinical trials for ovarian cancer.
GroPep sales up, tips new CEO next week
28 August, 2002 by Iain ScottAdelaide biotech GroPep has blamed the Sydney operations it took over when it acquired Biotech Australia earlier this year for most of the $6.89m loss it sustained in the 2001-02 financial year.
NHMRC kicks off new development funding scheme
28 August, 2002 by Melissa TrudingerThe National Health and Medical Research Council has awarded more than $5 million to 15 researchers seeking to commercialise their discoveries, in the first round of its new development grant scheme.
CK Life mulling state sweeteners
28 August, 2002 by David BinningHong Kong's Cheong Kong Holdings-backed biotech venture CK Life Sciences is yet to decide which state will house its Australian operations, the company said on Tuesday, as it weighs up offers from some very determined suitors.
